◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › APGE

Apogee Therapeutics, Inc. (APGE) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-26

Apogee Therapeutics, Inc. (APGE) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 261 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, APGE reported $0M in revenue and ($256M) in net income.

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.

Interactive charts & full statements →

APGE Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($286M)($217M)($93M)($31M)
Net Income($256M)($182M)($84M)($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

APGE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($83M)($78M)($71M)($73M)($63M)
Net Income($74M)($69M)($65M)($66M)($55M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

APGE Free Cash Flow History

APGE Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-31
Total Assets$937M$754M$401M$152M
Total Liabilities$33M$37M$22M$10M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive APGE viewer.

Other Companies in Biotechnology

← APGAll stocksAPH →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.